Insider filing · IMNM

Clay B Siegall bought $501K of Immunome (IMNM)

Executed Mar 27, disclosed Mar 31, 4 days later.

Over the 21 trading sessions from the disclosed entry session (Mar 31), the stock returned +12.7% (delay-adjusted); from the execution session (Mar 27), +15.9%. Derived: entry at the session's open, exit at the close 20 sessions later.

CS Clay B Siegall President and CEO profile →

Clay B Siegall (President and CEO) filed 5 Form 4 reports in the trailing twelve months (5 purchases, 0 sales), most often in Immunome, Inc. (IMNM). Across 5 priced purchase filings, the average 21-session return was +28.7% from execution and +24.2% from disclosure (delay-adjusted; derived). The largest single filing was $1000K of IMNM (46,511 sh × $21.50, as filed), executed Dec 18 2025.

IMNM Immunome, Inc. IMNM · Healthcare · 26 filings in 24 months ticker →

Healthcare · Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-dr…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→